Abbvie Inc.

Yingchun Li

Jijie Gu

Jonathan A Hickson

Susan Elizabeth Morgan-Lappe

Chung-Ming Hsieh

Ravi Chari

Lorenzo Benatuil

Yuliya Kutskova

Supriya Gupta

Camellia Zamiri

Dominic J Ambrosi

Erwin R Boghaert

Louie Naumovski

Maria Harris

Susan E Lappe

Xianhua Cao

Zhihong Liu

Deanna L Haasch

Ming-Jiu Chen

Tariq Ghayur

Jieyi Wang

Randy Bell

Edward B Reilly

Gillian A Kingsbury

Andrew C Phillips

Junjian Liu

Hua Ying

Suzanne M Norvell

Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity.

Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof

Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.

Therapeutic DLL4 binding proteins

DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis.

Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases characterized by aberrant DLL4 and/or VEGF expression or activity.

The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.

Dual variable domain immunoglobulins and uses thereof

Growing community of inventors

Buffalo Grove, IL, United States of America

Yingchun Li